Dr. Alex Kolevzon develops treatments to target the core symptoms of autism

Date Published: 
March 1, 2012

Dr. Kolevzon, Clinical Director of the Seaver Autism Center, develops new pharmacological treatments to target the core symptoms of autism. Dr. Kolevzon discusses his work with Insulin-like Growth Factor (IGF1), which increases neural communication and may ameliorate issues of learning and memory in individuals with autism. Small trials of IGF1 have begun with children with SHANK3 deletion, a genetic condition held by ~1% of individuals with autism. If successful, Dr. Kolevzon and the Seaver Autism Center will conduct trials with the larger autism population.